Applied StemCell Awarded ~USD 2 mil NIH grant for Advancing its TARGATT Technology for Therapeutic Gene Editing

·1-min read

Applied StemCell, Inc. (ASC), a leading gene editing company focused on the development of enabling tools for cell and gene therapy has been awarded close to $2.0 million US dollars in a Small Business Innovation Research (SBIR) grant from the NIH. This fast track Phase I/II grant award will support Applied StemCell (ASC) to advance and improve the efficiency of its proprietary TARGATT™ integrase technology for human gene therapies (referred to as the hTARGATT™) in a three part objective: (1) Develop and improve the efficiency of the TARGATT™ technology in human cell lines including primary cells and stem cells; (2) Develop therapeutic transgenes and demonstrate optimal integration efficiencies as a functional demonstration of the platform’s utility for ex vivo therapeutic applications; (3) Differentiate the above mentioned stem cells to desired somatic lineages and demonstrate regulatory induction of the transgenes.

Applied StemCell (ASC)’s approach will take advantage of the site-specificity and large DNA insertion capability of the serine integrase, PhiC31 (φC31) and engineer it to insert exogenous DNA into a defined and safe harbour locus in the human genome. The scope of the grant will also cover an unbiased detection and characterization of potential off-target insertion sites to ensure safety of this platform for therapeutic gene editing.

This study will provide useful insight into the applicability of the hTARGATT™ Gene Therapy platform and build the foundation for its use in gene therapy for potentially ten thousand monogenic human diseases.

View source version on


Maki Ogawa
Marketing Director, Applied StemCell, Inc.